OA11487A - Gene encoding labyrinthin, a merker for cancer. - Google Patents

Gene encoding labyrinthin, a merker for cancer. Download PDF

Info

Publication number
OA11487A
OA11487A OA1200000256A OA1200000256A OA11487A OA 11487 A OA11487 A OA 11487A OA 1200000256 A OA1200000256 A OA 1200000256A OA 1200000256 A OA1200000256 A OA 1200000256A OA 11487 A OA11487 A OA 11487A
Authority
OA
OAPI
Prior art keywords
lab
molécule
cdna
cancer
sequence
Prior art date
Application number
OA1200000256A
Other languages
English (en)
Inventor
James A Radosevich
Original Assignee
James A Radosevich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by James A Radosevich filed Critical James A Radosevich
Publication of OA11487A publication Critical patent/OA11487A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA1200000256A 1998-03-17 2000-09-18 Gene encoding labyrinthin, a merker for cancer. OA11487A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/040,485 US6166176A (en) 1998-03-17 1998-03-17 Cancer marker protein and peptides thereof

Publications (1)

Publication Number Publication Date
OA11487A true OA11487A (en) 2004-05-04

Family

ID=21911225

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000256A OA11487A (en) 1998-03-17 2000-09-18 Gene encoding labyrinthin, a merker for cancer.

Country Status (15)

Country Link
US (7) US6166176A (ru)
EP (1) EP1062346B1 (ru)
JP (2) JP2002512005A (ru)
CN (2) CN101260401A (ru)
AP (1) AP2000001917A0 (ru)
AT (1) ATE337400T1 (ru)
AU (2) AU762758B2 (ru)
BR (1) BR9908886A (ru)
CA (1) CA2323494A1 (ru)
DE (1) DE69932926T2 (ru)
EA (1) EA003735B1 (ru)
HK (1) HK1033151A1 (ru)
IL (1) IL138208A0 (ru)
OA (1) OA11487A (ru)
WO (1) WO1999047683A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US20050123545A1 (en) * 1999-11-08 2005-06-09 Wands Jack R. Diagnosis and treatment of malignant neoplasms
US6835370B2 (en) 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20030031670A1 (en) 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US7306919B1 (en) 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
JP2006502110A (ja) * 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
ATE414715T1 (de) * 2003-09-04 2008-12-15 Biomay Ag Hypoallergene polypeptide basierend auf aus fisch gewonnenem parvalbumin
JP2007535907A (ja) * 2003-11-14 2007-12-13 マサチューセッツ・インスティテュート・オブ・テクノロジー 抗ヒドロキシラーゼ抗体およびその使用
CN100457922C (zh) * 2005-10-20 2009-02-04 康哲医药研究(深圳)有限公司 检测酪丝亮肽抗肝癌效果的方法及所用试剂盒与基因芯片
GB201002627D0 (en) 2010-02-16 2010-03-31 Loxbridge Res Llp Aptamer based analyte detection method
WO2020123964A1 (en) * 2018-12-13 2020-06-18 Labyrx Immunologic Therapeutics (Usa) Limited Labyrinthin-based peptides for cancer immunotherapies and uses thereof
CN113993892A (zh) * 2019-01-08 2022-01-28 莱比锡免疫治疗(美国)有限公司 靶向迷路蛋白或其部分的构建体以及所述构建体的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816402A (en) * 1986-01-07 1989-03-28 Northwestern University Murine hybridoma and diagnostic antibody produced thereby
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5223604A (en) * 1991-06-25 1993-06-29 S.P.I. Synthetic Peptides Incorporated Pseudomonas exoenzyme s peptide composition and method
US5728819A (en) * 1996-08-02 1998-03-17 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US5994062A (en) * 1995-10-02 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Epithelial protein and DNA thereof for use in early cancer detection
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US6344548B1 (en) * 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US7135617B2 (en) * 1998-07-02 2006-11-14 Calgene Llc Diacylglycerol acyl transferase proteins
US6100077A (en) * 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
US7045326B2 (en) * 2001-02-23 2006-05-16 The Regents Of The University Of California Mono- and diacylglycerol acyltransferases and methods of use thereof
US20030161831A1 (en) * 2001-02-23 2003-08-28 Sylvaine Cases Mono-and diacylglycerol acyltransferases and methods of use thereof
US7417176B2 (en) * 2002-07-31 2008-08-26 Monsanto Technology Llc Diacylglycerol acyltransferase nucleic acid sequences and associated products
US8685679B2 (en) * 2004-11-04 2014-04-01 E I Du Pont De Nemours And Company Acyltransferase regulation to increase the percent of polyunsaturated fatty acids in total lipids and oils of oleaginous organisms
US8507754B2 (en) * 2009-01-31 2013-08-13 University Of North Texas Engineering lipids in vegetative tissues of plants
RU2636344C2 (ru) * 2010-06-28 2017-11-22 Коммонуэлт Сайентифик энд Индастриал Рисерч Организейшн Способы получения липидов

Also Published As

Publication number Publication date
EP1062346A1 (en) 2000-12-27
US6727080B1 (en) 2004-04-27
US20050208508A1 (en) 2005-09-22
US20100233711A1 (en) 2010-09-16
BR9908886A (pt) 2000-11-21
US6166176A (en) 2000-12-26
JP2002512005A (ja) 2002-04-23
WO1999047683A1 (en) 1999-09-23
AU2003204331B2 (en) 2008-02-07
EA200000845A1 (ru) 2001-08-27
CN100372938C (zh) 2008-03-05
US7635759B2 (en) 2009-12-22
AU2999699A (en) 1999-10-11
US8163883B2 (en) 2012-04-24
AP2000001917A0 (en) 2000-09-30
WO1999047683A9 (en) 1999-11-18
US20110110963A1 (en) 2011-05-12
DE69932926T2 (de) 2007-05-24
AU762758B2 (en) 2003-07-03
EA003735B1 (ru) 2003-08-28
CN101260401A (zh) 2008-09-10
DE69932926D1 (de) 2006-10-05
IL138208A0 (en) 2001-10-31
EP1062346B1 (en) 2006-08-23
CA2323494A1 (en) 1999-09-23
JP2009165492A (ja) 2009-07-30
CN1301302A (zh) 2001-06-27
HK1033151A1 (en) 2001-08-17
ATE337400T1 (de) 2006-09-15
US20100112582A1 (en) 2010-05-06
US20080249284A1 (en) 2008-10-09
US7329743B2 (en) 2008-02-12

Similar Documents

Publication Publication Date Title
US8163883B2 (en) Gene encoding labyrinthin, a marker for cancer
AU700915B2 (en) Lung cancer marker
CA2281952C (en) Compounds for immunotherapy of prostate cancer and methods for their use
Cho et al. Identification and characterization of a novel cancer/testis antigen gene CAGE
JP4204642B2 (ja) 前立腺に特異的な膜抗原
KR100380503B1 (ko) 흑색종관련항원성폴리펩티드,그에피토프및흑색종에대한백신
JP5640237B2 (ja) 癌関連抗原をコードする単離された核酸分子、その抗原そのものおよびその使用
US20070015907A1 (en) Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
US20090035819A1 (en) CA125 gene and its use for diagnostic and therapeutic interventions
JP4270523B2 (ja) 乳癌の処置および診断のための組成物および方法
JP2008043337A (ja) 乳癌の処置および診断のための組成物および方法
NZ503729A (en) Secreted mammary-specific breast cancer protein (mammaglobin) and vaccines
KR20010075418A (ko) 유방 특이적으로 분비되는 유방암 단백질인 마마글로빈
MXPA00008836A (en) Gene encoding labyrinthin, a marker for cancer
NZ507014A (en) A gene encoding a novel marker for cancer
WO2001073062A1 (fr) Nouveau polypeptide, antigene prostatique specifique membranaire 18, et polynucleotide codant pour ce polypeptide
AU2008202039A1 (en) Gene encoding labyrinthin, a marker for cancer
JP2008289472A (ja) 乳癌の処置および診断のための組成物および方法
WO2001070792A1 (fr) Nouveau polypeptide, tyrosinase humaine 12, et polynucleotide codant pour ce polypeptide
WO2001094531A2 (fr) A novel polypeptide, globuline humaine 12 de l'uterus, et polynucleotide codant ce polypeptide
WO2001094403A1 (fr) Nouveau polypeptide, sous-unite de proteine d'activation de la transcription humaine 14, et polynucleotide codant ce polypeptide